Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488184 | 0.97 | IDH1 (0.42) | IDH1MCHR1MCHR2SYKAXL | |
| SCHEMBL17488080 | 0.86 | IDH1 (0.40) | IDH1MCHR1MCHR2NTRK1 | |
| SCHEMBL17488071 | 0.76 | CXCL8 (0.42) | IDH1MCHR1MCHR2NTRK1SCN9A | |
| SCHEMBL17488070 | 0.73 | NOD1 (0.52) | NTRK1SCN9A | |
| SCHEMBL17488202 | 0.73 | NOD1 (0.46) | IDH1MCHR1MCHR2NTRK1 | |
| SCHEMBL17488072 | 0.70 | CXCL8 (0.43) | IDH1NTRK1SCN9A | |
| SCHEMBL17488027 | 0.68 | MCHR1 (0.41) | MCHR1AXL | |
| SCHEMBL17488075 | 0.67 | KMT2A (0.52) | IDH1NTRK1 | |
| SCHEMBL17488198 | 0.67 | IDH1 (0.40) | IDH1MCHR1SYKNTRK1 | |
| SCHEMBL17488287 | 0.65 | HPGD (0.51) | MCHR1MCHR2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | IDH1 1717/4885MCHR1 2605/4885MCHR2 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.